2024-04-26 09:45:47
The 2024 vaccination schedule is made public today. Developed by the Ministry of Health, after advice from the High Authority for Health (HAS), the vaccination schedule brings together all the general and specific vaccination recommendations, applicable depending on age.
The new features of the 2024 vaccination schedule aim to better protect against pneumococcal infections and meningococcal infections but also measles and shingles.
Public Health France is publishing HPV vaccination coverage estimates today in its Vaccination bulletin, taking into account vaccinations carried out in colleges as well as in private settings. Data indicates that HPV vaccination coverage is increasing.
Launched in colleges in the fall of 2023, the HPV vaccination campaign for girls and boys in fifth grade represents a major public health challenge: improving vaccination coverage against this infection, responsible for 6,000 new cases of cancer. and 30,000 precancerous lesions of the cervix each year.
What’s new in the 2024 vaccination schedule
Vaccination against pneumococcal infections
The new 15-valent conjugate vaccine Vaxneuvance® has been integrated into the strategy for preventing pneumococcal infections in infants and people aged under 18 years. When it becomes available and supported, the 15-valent Vaxneuvance® conjugate vaccine and the 13-valent Prevenar13® conjugate vaccine may be used interchangeably, particularly as part of the compulsory vaccination of infants born since January 1, 2018.
In adults, the integration into the vaccination schedule of the new 20-valent conjugate vaccine Prevenar 20® with a single dose vaccination schedule makes it possible to simplify the vaccination schedule currently in force. As soon as it is available and supported, the Prevenar 20® vaccine can be used preferentially in the strategy for preventing pneumococcal infections in people aged 18 and over.
Vaccination against invasive meningococcal infections
Tetravalent ACWY vaccination is recommended for infants and adolescents aged 11 to 14 years. A catch-up vaccination against ACWY meningococci is recommended for people aged 15 to 24. These recommendations can be implemented as soon as vaccines are covered under common law. Note that the vaccination obligation against serogroups ACWY and B in infants will come into force on January 1, 2025 after the publication of the regulatory texts.
Shingles Vaccination
The Shingrix® vaccine is now integrated into the shingles vaccination strategy. It is also recommended for immunocompromised older adults aged 18 and over. Preferential use of this vaccine is recommended in people aged 65 and over. These recommendations can be implemented as soon as the Shingrix® vaccine is covered under common law.
Measles Vaccination
To ensure better protection, an additional dose of MMR is recommended for people born after 1980 and who received a first vaccination before the age of one.
The vaccination schedule may be updated based on vaccination-related news. Health professionals are invited to regularly consult the Ministry of Health website on which the dated version is published.
An increase in HPV vaccination
Launched in the fall of 2023, the HPV vaccination campaign for girls and boys in fifth grade made it possible to offer free and accessible vaccination to as many people as possible, but also to raise awareness among young people and parents of the importance of this vaccination. The information campaign deployed during the college vaccination also had a probable positive effect on vaccination in the city.
Thus, among 12-year-old adolescents, that is to say those mainly concerned by the middle school vaccination campaign, estimates of vaccination coverage against human papillomavirus infections increase by 17 points at the end of 2023 compared to the end of 2022, reaching 48% (55% for girls and 41% for boys).
Likewise, vaccination coverage against papillomavirus infections is increasing among young people aged 15 and over: in 2023, it is 55% for one dose in young girls aged 15 (vs 48% the previous year ) and 45% for the complete scheme among girls aged 16 (vs. 41% in 2022).
In young boys, vaccination against HPV infections has been recommended for three years. Vaccination coverage in 2023 is 26% for the first dose at age 15 vs. 13% the previous year, an increase of 13 points. 2-dose vaccination coverage (full schedule) for young boys aged 16 is also increasing (16% in 2023 vs. 8.5% in 2022).
This upward trend must continue, because vaccination prevents up to 90% of HPV infections that cause various cancers, the most common of which is cervical cancer.
Very common infections
About 8 in 10 people are exposed to this virus during their lifetime. In 60% of cases, infection occurs at the start of sexual life. Condoms only provide partial protection against infection. Human papillomavirus infections can progress to different cancers: cancers of the cervix, anus, vagina, vulva, penis and certain ENT cancers.
Vaccination against human papillomavirus infections has been recommended since 2007 in France, mainly in young girls and since January 1, 2021, in boys. Indeed, men participate as much in the transmission of infection in the population and are also affected by HPV infections. Vaccination also protects them against the occurrence of lesions, and indirectly protects women.
HPV vaccination is recommended for girls and boys aged 11 to 14 with a 2-dose schedule six months apart. Furthermore, for those who were not vaccinated at 14 years old, catch-up vaccination is recommended for young women and young men between 15 and 19 years old inclusive: three doses are then necessary.
Consult the 2024 vaccination calendar
Consult the national Vaccination Bulletin
Consult the regional Vaccination Bulletins
Consult the 2023 vaccination coverage data published on the Géodes website
Download the press release in PDF
Office of Frédéric Valletoux
Mel : [email protected]
01 40 56 76 92
General Directorate of Health
Mel : [email protected]
01 40 56 84 00
Public health France
Mel : [email protected]
Stéphanie Champion: 01 41 79 67 48
Camille Le Hyaric : 01 41 79 68 64
Céline Coulaud: 01 41 79 68 22
1714126149
#European #Vaccination #Week #Publication #vaccination #schedule #update #encouraging #results #vaccination #human #papillomavirus #HPV #infections